Gencurix

6 articles about Gencurix

• Gencurix Obtains Approval for Companion Diagnostic of Digital PCR-based EGFR Mutation Test

  6/14/2023

  Gencurix, a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.

• Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company's Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX

  6/5/2023

  Gencurix, a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesWell BCT, with Oncotype DX, the globally top-selling test, confirming its outstanding performance.

• Gencurix wins FDA EUA for COVID-19 Test Kit

  6/24/2020

  A Korean molecular diagnostic company, Gencurix, Inc., has announced that they have received U.S. Food and Drug Administration (FDA)'s Emergency Use Authorization (EUA) for its GenePro SARS-CoV-2 Test.

• New publication shows different result of risk classification between GenesWell BCT and Oncotype DX in breast cancer patients 50 years old or younger.

  8/6/2019

  Gencurix, Inc., a company dedicated in development and market of innovative molecular diagnostics, announced the publication of a new study onFrontiers in Oncology comparing GenesWell™ BCT, a prognostic multigene test, with Genomic Health’s Oncotype DX in patients with early-stage breast cancer

• Gencurix Publishes Companion Diagnostics Technology with Reflection of Quality of Nucleic Acid Samples in International Journal

  1/11/2018

  Gencurix announced that the nucleic acid quality index (iQC index), allowing the measurement of the quality of the nucleic acid in molecular diagnosis is published in the Journal of Scientific Reports on Jan 2.

• Gencurix Publishes A Clinical Validation Study On GenesWell BCT, A New Breast Cancer Prognostic Test

  3/28/2017